Baxter International BAX Pharmaceuticals — Depreciation

Other segment segments

Similar metrics at other companies

IFFPharma Solutions — D&A

$34.25M-1.4%

BTSGPharmacy Solutions — Depreciation And Amortization Expense From Reportable

$25.33M-7.9%

LHBiopharma Laboratory Services — Depreciation

$28.6M0.0%

IFFPharma Solutions — Depreciation Expense, Add-Back

-$10M-150%

BTSGPharmacy Solutions — Cost Of Goods And Services Sold Depreciation And Amortization

$27.91M-5.0%

WSTContract-Manufactured Products — Depreciation, Depletion and Amortization

$7.6M+22.6%

Questions, answered.

What is Baxter International's pharmaceuticals — depreciation?

Baxter International (BAX) reported pharmaceuticals — depreciation of $16M in Q1 2026.

How has Baxter International's pharmaceuticals — depreciation changed year-over-year?

Baxter International's pharmaceuticals — depreciation decreased by 0.0% year-over-year, from $16M to $16M.

What is the long-term trend for Baxter International's pharmaceuticals — depreciation?

Over 4 years (2021 to 2025), Baxter International's pharmaceuticals — depreciation has grown at a -2.2% compound annual growth rate (CAGR), from $71M to $65M.

What does pharmaceuticals — depreciation mean?

The non-cash expense representing the aging and usage of physical assets in the Pharmaceuticals segment.

How do you interpret pharmaceuticals — depreciation?

Consistent depreciation is expected; sudden spikes may indicate significant new capital investment or asset write-downs.

How does pharmaceuticals — depreciation compare across companies?

Standard for capital-intensive manufacturing segments; peers with newer facilities may show higher depreciation.